Eyeworld

I N FOCUS 40 | EYEWORLD | DECEMBER 2019 EXAMINING PRESBYOPIA TREATMENTS by Liz Hillman EyeWorld Editorial Co-Director "It appears that there are less bothersome dysphotopsias and very high quality of vision, and those are all things we're thinking about when we're thinking about any light-splitting technologies: 1) quality of vision, 2) range of vision, and 3) unwanted side effects," Dr. Yeu said. PanOptix is currently the only FDA- approved trifocal in the U.S. Bausch + Lomb is in the midst of a clinical trial with its enVista MX60EF trifocal IOL, enrolling its first patient for the 500-patient study in June 2018. Trifocals that are currently being used outside of the U.S., in addition to PanOptix, are the AT LISA (Carl Zeiss Meditec), FineVision (PhysIOL), and RayONE Trifocal (Rayner). Dr. Yeu, Robert Cionni, MD, and Kerry Solomon, MD, who were involved with the Pan- Optix clinical trial, and Eric Donnenfeld, MD, shared their thoughts and experience with this F or years, ophthalmologists have been hearing about the success with trifocal IOLs from outside the U.S. With FDA approval of the AcrySof IQ PanOptix trifocal IOL (Alcon), U.S. ophthal- mologists now are beginning to use this option, drawing confidence from experience reported overseas. "What I appreciate the most is that because of the span of time that has passed where there has been availability internationally, it really gives us the breadth of what the international experience has been like," Elizabeth Yeu, MD, said. "Right now the experience allows us to recognize that there is a reason this lens has taken over the market for multifocals overseas, where it has been a leader in the multifocal space. It gives me some greater confidence and trust that the lens technology works as it's sup- posed to given the fuller range of vision. U.S. ophthalmologists start to experience trifocal IOLs PanOptix IOL implanted following cataract surgery. Source: Eric Donnenfeld, MD At a glance • The first trifocal IOL to receive FDA approval was PanOptix (Alcon) in August 2019. The enVista trifocal IOL (Bausch + Lomb) is in clinical trials in the U.S. • Surgeons report positive patient experience with Pan- Optix thus far with good range of vision at near, intermediate, and distance. • They also report fewer dys- photopsias often associated with multifocal and extended depth of focus IOLs. • There are characteristics that should be taken into account when considering a patient as a candidate for a trifocal IOL. Contact information Cionni: rcionni@theeyeinstitute.com Donnenfeld: ericdonnenfeld@gmail.com Solomon: kds@cepmd.com Yeu: eyeulin@gmail.com

• Blank Page
• Blank Page (1)